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Abstract: Phage therapy is becoming a widely recognized alternative for fighting pathogenic bacteria
due to increasing antibiotic resistance problems. However, one of the common concerns related to
the use of phages is the evolution of bacterial resistance against the phages, putatively disabling
the treatment. Experimental adaptation of the phage (phage training) to infect a resistant host has
been used to combat this problem. Yet, there is very little information on the trade-offs of phage
infectivity and host range. Here we co-cultured a myophage FCV-1 with its host, the fish pathogen
Flavobacterium columnare, in lake water and monitored the interaction for a one-month period. Phage
resistance was detected within one day of co-culture in the majority of the bacterial isolates (16 out of
the 18 co-evolved clones). The primary phage resistance mechanism suggests defense via surface
modifications, as the phage numbers rose in the first two days of the experiment and remained
stable thereafter. However, one bacterial isolate had acquired a spacer in its CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeat)-Cas locus, indicating that also CRISPR-Cas defense
was employed in the phage-host interactions. After a week of co-culture, a phage isolate was obtained
that was able to infect 18 out of the 32 otherwise resistant clones isolated during the experiment.
Phage genome sequencing revealed several mutations in two open reading frames (ORFs) likely to be
involved in the regained infectivity of the evolved phage. Their location in the genome suggests that
they encode tail genes. Characterization of this evolved phage, however, showed a direct cost for the
ability to infect several otherwise resistant clones—adsorption was significantly lower than in the
ancestral phage. This work describes a method for adapting the phage to overcome phage resistance
in a fish pathogenic system.
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1. Introduction
Phage therapy is a widely recognized and studied method for combating bacterial pathogens.
It is gaining increased attention as an alternative or addition to antibiotic treatment, due to the global
crisis of emerging antibiotic resistance. However, subjecting bacteria to phages raises concerns of
phage resistance in pathogenic bacterial populations. Bacteria can use either passive (mutations in the
phage receptors) or active (e.g., restriction-modification and Clustered regurarly Interspaced Short
Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) defense, actively degrading phages)
mechanisms to prevent the phage infection, see, e.g., [1,2]. However, phage resistance is often costly
for the bacteria and may cause loss of virulence, e.g., [3–5], suggesting that locally appearing phage
resistance might not be a problem. On the other hand, the continuous arms race between bacteria
and phage also assures the rise of phage progeny that have evolved to infect the resistant bacteria.
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Phage can quickly adapt by changing a part or parts of their route of infection and/or bypass active
resistance mechanism via genomic mutations or directly inhibiting CRISPR-Cas defense [6,7]. Using
phage-bacterium coevolution as a tool could be an important part in developing phage therapy.
Methods for phage training have been developed for selecting evolved phages that are better
suited for phage therapy purposes. The earliest phage training method, called Appelmans experiment,
originates from the early 1920s and has been reviewed recently [8]. Other examples include co-culture
of bacteria and phage and serial passage of phage. Such experiments with Pseudomonas aeruginosa and
its phages [9,10] resulted in evolved phages that were more efficient in reducing bacterial densities.
Flavobacterium columnare, the causative agent of columnaris disease in fish, is a severe pathogen in
freshwater fish farming worldwide causing major economic losses [11]. We have previously tested
phage in the treatment of, as well as as a prophylactic against, columnaris disease with promising
results. In F. columnare phage resistance evolves mainly through surface modifications, which results in
fitness costs via loss of motility and virulence [12,13]. The cells of F. columnare form different colony
morphologies under laboratory conditions that differ in their ability to glide on surfaces and cause
disease. Phage resistance is seen as a change in colony morphology from rhizoid (Z, expression of
gliding motility) to rough (R, non-gliding) [12,13] and similar connections have been seen in other
model systems [14]. In naturally evolving F. columnare populations, surface resistance has not been
detected, although data from the coevolving phage population indicate counter-adaptations to such
resistance mechanisms [15].
However, it is still unclear how the phage treatment would affect phage susceptibility in the case
of F. columnare—would there be a problem with phage resistance? Previously, a controlled experiment
on the coevolution of F. columnare and phage was performed to study the hosts CRISPR-Cas spacer
acquisition [16]. Here, we aimed to understand phage response during coevolution and the cost
of ability to infect wider range of the otherwise resistant bacterial clones in phage phenotype. The
occurrence of phage resistance and phage ability to overcome the developed host resistance was
studied with phage-host pair originating from our previous study, host strain B245 and a myophage
FCV-1 with a linear 47 kbp genome [15,17]. Host and phage were incubated for a four-week period
in lake water without nutrient additions. It is known that cells of F. columnare survive in lake water
for at least a 5-month period [18]. Phages infecting F. columnare isolated thus far do not have a broad
genetic or morphological variety [15,17]. Hence, one option is that F. columnare could be combated
more efficiently with evolved, broad-spectrum host range phages.
During the experiment, one evolved phage isolate was selected for detailed characterization
because of its capability to infect most of the bacterial clones isolated that were resistant to the ancestral
phage. The cost for the ability to overcome phage resistance was detected in weaker adsorption.
We pinpoint the molecular level changes in the evolved phage genome. The method is a simple one
and could be used to develop evolved phages within this system and our results encourage the use of
experimental evolution in producing phages for phage therapy applications.
2. Results
2.1. Bacteria and Phage during the Experiment
Monitoring of the phage and bacterial populations during the 29-day experiment (Figure 1A)
showed that in the first two days, bacterial cell numbers reached the highest concentration in both
treatments, with (PB) and without the phage (B). Additionally, the phage titer (PFU/mL) increased
approximately three logs (from 104 PFU/mL to 107 PFU/mL) during these first days, remaining stable
until the end of the experiment. In the phage only treatment, the phage numbers remained stable
throughout the experiment (Figure 1B).
Antibiotics 2020, 9, 291 3 of 11
 
3 
 
Figure 1. (A) Mean and standard deviation of colony forming units per mL (CFU/mL) of three 
replicates of Flavobacterium columnare strain B245 during the four-week experiment with phage FCV-
1 and without phage. (B) Mean and standard deviation of plaque forming units per ml (PFU/mL) of 
phage FCV-1, with B245 and FCV-1 without bacteria. 
2.2. Phage Resistance Detected by Morphotype and CRISPR Spacer Acquisition 
F. columnare evolves resistance against phage mainly via surface modifications, which cause a 
colony morphology change from the ancestral rhizoid (Z) to rough (R) [12]. Thus, the proportion of 
rhizoid (generally sensitive for phage) and rough (generally resistant to phage) colonies during the 
experiment was also monitored. Here, the phage-exposed bacteria formed more rough colonies 
starting from the first day, and the proportion of rough colonies was highest after 7 days of co-
culture. At the 14th day, sampling the proportion of rhizoid colonies had again increased, and at 
four weeks, the proportion of rhizoid colonies was higher than the rough colonies (Figure 2). The 
two CRISPR arrays of F. columnare, both of which contain pre-existing phage-targeting spacers [15], 
were checked for acquisition of new spacers during the co-culture. From 65 bacterial isolates that 
were tested, one isolate from two weeks of co-culture had acquired an additional spacer in its RNA 
targeting type VI-B array (5′-CATTGCAATGAGTGGATAGATGTGCAATG-3′). The spacer crRNA 
matched the putative large subunit terminase on the non-coding strand of FCV-1 genome and was 
thus not complementary to the predicted mRNA of this gene. Inability to bind RNA is in contrast 
with the other pre-existing FCV-1 targeting spacers in this locus that are invariably complementary 
to mRNA. 
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2.3. Phage Infectivity against the Evolved Bacteria
Infectivity of co-evolved (and ancestral phage) phage isolates (45 isolated phage plaques) from the
experiment was tested against all the bacterial isolates (including ancestral host) collected during the
experiment (55 bacterial clones), including rhizoid and rough morphotype colonies from phage and
bacteria (PB) and bacteria alone (B) treatments (Figure 3). In general, the clones from bacteria alone were
all sensitive to all phage isolates, and clones from co-cultivation were resistant. The number of generally
resistant clones was 32 out of the 35 tested. One of the triplicates demonstrated different interaction
dynamics, since bacterial isolates were detected that were sensitive to most of the phage isolates.
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Figure 3. Infectivity of the ancestral phage and phage isolates from one week and two weeks against
the original bacteria and isolates from one week and two weeks. Black squares indicate infection and
white squares indicate no infection. Colony morphology of the bacterial isolate is indicated on the
right, where a square indicates rhizoid and a circle indicates rough. * = Ancestral phage. Numbers
correspond the strains in Table 1 (1 being the ancestral strain B245). An arrow at the bottom indicates
the evolved phage FCV-1.01. B = bacteria, P = phage, w = with, wo = without.
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Table 1. Titers (PFU/mL) of ancestral FCV-1 and evolved FCV-1.01 on selected isolates (number in bold
before strain corresponds the bacterial strains marked in Figure 3).
Phage Titer (pfu/mL)
Bacteria FCV-1 FCV-1.01
C4 1,1 × 1010 1,1 × 1010
1 ancestral B245 1,3 × 1010 1,0 × 1010
2 (1 week), sensitive1 rhizoid 6,0 × 107 1,4 × 1010
3 (1 week) resistant1 rhizoid * 1,1 × 1010
4 (1 week), resistant1 rough NA 1,0 × 1010
5 (1 week), resistant1 rhizoid ** 1,1 × 1010
6 (1 week), resistant1 rough NA 4,9 × 1009
7 (2 weeks), resistant1 rhizoid, spacer added 0 2,0 × 1010
1 resistant or sensitive to most of the phage isolates, * inhibition of growth (but no plaques) was detected in 1000-fold
dilution, ** inhibition of growth (but no plaques) was detected in 10-fold dilution, NA = not assigned.
One phage isolate differed from other phage isolates by being able to infect 41 out of the 55 tested
bacterial isolates, whereas the other phage isolates from the experiment infected approximately 20 out
of 55 isolates. In addition, the evolved phage was able to infect 18 out of the 32 otherwise-resistant
bacterial clones. The titers of the ancestral FCV-1 and this evolved phage FCV-1.01 were compared on
the original host, colony variants and selected isolates from the experiment (Table 1). The evolved
phage FCV-1.01 was able to infect all while the original FCV-1 was able to infect one of the rhizoid
isolates from week one (in addition to original host).
2.4. Ability to Infect Phage Resistant Clones Has a Direct Cost on Phage Adsorption
The adsorption of the ancestral and evolved phage to the cells was measured using the host C4
soft colony type. Evolved phage had a weaker adsorption than the ancestral phage FCV-1 (Figure 4).
In 10 min, approximately 63% of the ancestral phage had been adsorbed while for the evolved phage
the amount was approximately 17%. We aimed to determine other life cycle parameters of both phages
as well but were not able to replicate the experiments.
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2.5. Nucleotide Level Differences Show Changes in Putative Tail Proteins
Sequencing of the evolved phage enabled a comparison to the ancestral phage genome in
nucleotide level (Figure 5). Interestingly, some of the mutations in the evolved phage are in the same
area as in phages that have been previously isolated from aquaculture setting [15]. Mutations were
concentrated in the 25 kbp area of the 46 kbp long genome, and as was also seen in the phages from
nature, the left end of the genome was more conserved, while the right end was more variable. The
two ORFs (ORFs 35 and 36) in the 25 kbp are in between several putative tail genes and are most likely
responsible for encoding parts of the tail structure. However, no function can be predicted due to
unreliable hits in BLASTp and HHPred. In addition, most of the ORFs at the right end of the genome
are missing a putative function but there are ORFs that are putatively responsible for DNA metabolism
(e.g., ssDNA binding protein).
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3. Discussion
Bacteria and phage are in a continuous arms race [2,19,20]. For phage therapy to become a reality,
many aspects of the coevolution need to be resolved before adding phages to, e.g., aquaculture systems.
The abundant use of chemical treatments over decades has caused the ongoing antibiotic resistance
crisis, demonstrating that eradicating evolving biological material (bacteria) requires well-planned
methods and thorough risk analysis. The applicability of phage in preventing and treating bacterial
diseases has been shown to be efficient, and well-designed phage therapy provides a serious tool
for combatting antibiotic-resistant bacteria [21]. Prevention of columnaris disease (causative agent
F. columnare) with phage has been tested previously [22,23]. Here, we focused on the phage resistance
in F. columnare and characterized the counter-adaptation by the phage. We detected one phage
isolate that was able to overcome most of the evolved resistance. The cost for the ability to infect the
otherwise-resistant bacterial clones was detected as weaker adsorption in the evolved phage.
Previously, we showed the molecular level detail on the phage-bacterium coevolution under
semi-natural fish farming conditions over the course of several years [15]. The present study was a
natural continuation for the field data, and we used the same host and phage isolate but followed
the coevolution in a short time frame in a closed system. We were able to detect a rapid increase in
both phage and bacterial population sizes that then remained stable for the rest of the experiment.
There were only small fluctuations in phage and bacterial numbers after the first rapid rise, suggesting
passive primary resistance in bacteria. Lake water was not filtered for the experiment and particles for
biofilm growth were present that could promote phage production and susceptibility as was seen with
addition of mucin [23]. Here, we did not add resources, which would have likely reduced the cost
in terms of resistance mutations [24–27]. However, one bacterial clone was isolated after two weeks
of co-culture with an added spacer in its type VI-B CRISPR-Cas locus spacer array. Indeed, spacer
acquisition events in both identified CRISPR-Cas loci of F. columnare have been described [16]. Here,
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the addition of spacer indicates that a small proportion of the bacterial population was still sensitive
for phage allowing active CRISPR-Cas spacer acquisition. Since the phage pressure outside the cells
was high, it is supposed that the cells rely on other defense mechanisms rather than CRISPR-Cas, while
CRISPR-Cas could be a way to drive the phage population to extinction [28]. In addition, the type VI-B
CRISPR-Cas is likely to be involved in cellular dormancy, thus preventing phage production [29].
In F. columnare the change of colony morphology is spontaneous, but also inducible by
starvation [18] and the presence of phage [12]. When incubated together with phage in lake water,
the proportion of rough colonies started to rise among the rhizoid. After one week of incubation,
the proportions stabilized to approximately 50% of each. This also suggests that the primary defense
of this bacterium in these conditions is to alter the gliding motility machinery and surface structures.
The information of the phage receptors in F. columnare is missing, but they are likely to be part of the
gliding motility machinery, as has been proposed in F. johnsoniae [30,31]. It seems that the rough colony
type is costly for the bacteria, as it is prone to revert back to the rhizoid type, supporting the fact that
only the rhizoid type is isolated from the nature and fish farms [32].
While testing the infectivity of the phage isolates obtained during the co-culture, one isolate
from 7th day time point was significantly more able to infect the otherwise resistant bacterial clones.
The evolved phage was able to infect some of the rough isolates, despite the common phage resistance
displayed by this colony type [12,33]. The efficiency of plating of the ancestral and the evolved phage
was compared against some of the bacterial clones isolated from 7th day and 14th day time points. The
evolved phage was equally efficient in producing plaques on all of the bacteria except for a slight drop
in titer on one rough colony type isolate. The ancestral phage FCV-1 infected only the ancestral host
and, with lower efficiency, one rhizoid isolate. The isolate with an extra spacer was resistant to the
ancestral FCV-1.
Sequencing of the evolved phage genome indicated especially two ORFs (ORF35 and ORF36)
involved in the ability to infect the otherwise resistant bacterial clones due to several nucleotide
differences compared to the ancestral phage. No function for these ORFs was predicted, but their
position in the tail module, between the tail proteins (putative baseplate and distal tail protein), suggests
that they are tail proteins. The same ORFs were suggested to be related to host recognition according to
the genomic data from a long-term study from nature [15]. The most understood phage tail structure
is that of phage T4 [34,35]. In T4, the long tail fiber is a product of four different genes (and requires
additional protein products to function). It interacts with both OmpC and LPS on the host surface,
receptors that are used for host binding and moving on the surface of the cell to find a suitable site
for infection. Previously, it has been shown that mutations especially in the gp37 of the tail fiber are
responsible for adsorption specificity in T4 [36]. It is likely that ORF35 and ORF36 are part of tail fiber
in FCV-1 and function as host recognition and/or attachment and mutations in these genes result in
ability to infect wider range of the bacterial clones and affects the adsorption efficiency, as the genetic
data can be associated with the phage phenotypic data. We observed a difference in the adsorption
of the ancestral and evolved phage. A cost of the ability to infect wider range of the bacterial clones
was detected as lower adsorption of the evolved phage. In contrast, Sergueev et al. [37] obtained
an adapted phage in methicillin-resistant Staphylococcus aureus (MRSA) with similar adsorption to
sensitive and resistant strains as the ancestral phage, indicating other phage resistance mechanisms
than cell surface modifications. While it is known that small proportions of phage populations have an
exceptionally low adsorption rate suggested to function as a survival strategy [38], the low adsorption
in FCV-1.01 is likely to be the result of a cost from the evolved ability to infect wider range of the
otherwise resistant bacterial clones.
It seems that the aquatic environment and the interaction of phage and fish mucus together
with the external nature of the columnaris disease provide a promising ground for developing phage
therapy in this system for aquaculture settings. However, the observed diversity within the thus far
isolated phages infecting F. columnare has been limited [15,17], hampering the development of phage
cocktails containing several types of lytic phages. Thus, phage adaptation and expansion of the ability
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to infect wider range of the bacterial clones could be future methods to combat the pathogen as has
been described, for example, in phage T7 [39]. In addition, host range can be engineered synthetically
by designing targeted variations in receptor binding proteins [40].
Although our approach to studying coevolution is an oversimplification compared to the
environment at the fish farm and the ways the system would evolve in the fluctuating environment
with the pathogen host (fish) present, the approach presented here could still have applicability in
preparing phage cocktails, as has been done in phage therapy since the beginning of phage research [8].
Additionally, we see that the phage resistance countered by the phage with mutations especially in
ORFs 35 and 36. However, the reduced adsorption efficiency might select against this phage in a
real-life system and is possibly detected here only because of the static environment. These results
suggest that it is important to monitor the trade-offs of increased ability to infect a wider range of
the bacterial clones versus phage life cycle in the case of producing variants in laboratory conditions.
Whether the phage isolated in this study could also be more efficient in phage therapy, as was shown
for Pseudomonas aeruginosa [10], remains to be studied. In case the evolved phage would be more
virulent it would be feasible to evolve such phages for phage cocktails.
4. Materials and Methods
4.1. Bacteria and Phage
Bacteria and phage used in the study have been described previously; see [17] for phage FCV-1
and F. columnare strain B245. Furthermore, we used strain C4, a soft colony morphotype variant [41],
for phage life cycle experiments, as the phage propagation has not been successful in liquid with
other strains, although phage forms plaques on the soft agar overlay. Shieh [42] medium was used
in all cultivations with 1% agar (Thermo Fisher Scientific, Waltham MA, USA) in plates and 0.7% in
overlay agar.
4.2. Coevolution Experiment in Lake Water
Lake water was collected from the surface layer of a boreal lake Leppavesi in Central Finland
(N 62.267670, E 25.910923), autoclaved for 20 min at 121 ◦C, and stored at +4 ◦C before use. Phage
and bacteria (PB), only bacteria (B) and only phage (P) were inoculated in 40 mL of lake water in
triplicates. Bacterial density was adjusted to 1 × 104 CFU/mL, and phage was added to multiplicity
of infection (MOI) of 1. The cultures were maintained under constant agitation (50 rpm) throughout
the experiment (29 days) at 23 ◦C. Both bacteria and phage were sampled from each treatment and
CFU/mL and PFU/mL were determined by standard plating methods.
4.3. Sampling
Both bacterial (CFU/mL) and phage (PFU/mL) numbers were measured and the distribution of
rhizoid (Z) and rough (R) colony morphotypes was monitored. Single colonies of both morphotypes
(three of each in each replicate) were picked from PB and B and cultivated in 1 mL Shieh and stored in
10% glycerol (Sigma Aldrich, Saint Louis, MO, USA) and 10% FCS (Thermo Fisher Scientific, Waltham,
MA, USA) in −80 ◦C for further analysis (total of 360 colonies throughout the experiment). Single
plaques were picked into 500 µL Shieh from PB and B and stored in 10% glycerol in −80 ◦C.
4.4. Infectivity of Isolated Phage
Evolved phage plaque isolates (from four time points; one and two days and one and two weeks
from PB and two weeks from B) were tested against bacterial isolates from PB and B from one week
and two weeks, three isolates per replicate from B, and six isolates per replicate from PB, resulting in
45 phage isolates against 55 bacterial isolates (including ancestral phage and bacteria). One milliliter of
o/n grown bacteria was added to 9 mL of soft agar and plated on top of an agar plate. Plaque lysates
were spotted on the bacterial lawn as such and in ten- and hundred-fold dilutions for the detection
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of individual plaques. On the selected strains, phage infectivity was measured by mixing 100 µL of
ten-fold dilutions of phage lysate with 300 µL of o/n grown bacteria in 3 mL of soft agar and poured on
an agar plate.
4.5. Adsorption Test
Adsorption of the original FCV-1 and evolved phage isolate FCV-1.01 was compared using
F. columnare strain C4 as a host. The adsorption tests were performed following the procedure of
Kropinski [43] in triplicates. In brief, bacteria were grown to logarithmic phage, diluted and divided
into 9 mL cultures. Medium without bacteria was used as a control. Approximately 3 × 105 PFU was
added in 1 mL volume. Samples (50 µL) were taken to eppendorf tubes with 950 µL of precooled
medium including chloroform (VWR, Radnor, PA, USA). Number of free phages was determined from
the plaque forming units and used for calculating the percentage of adsorbed phages.
4.6. Sequencing of the Phage Genome
Genome of the evolved phage FCV-1.01 was extracted and sequenced and compared to the
original FCV-1 [15]. In brief, filtered phage lysate was treated with RNase and DNase and phages
were precipitated using ZnCl2 (40 mM), pelleted and resuspended to TES-buffer (0.1 M Tris-HCl pH 8;
0.1 M EDTA; 0.3% SDS). Protease K was used for the release of genomic DNA which was purified
using columns from DNeasy Blood&Tissue Kit (Qiagen, Hilden, Germany). Sequencing was done
commercially with Illumina MiSeq at the sequencing unit of Institute for Molecular Medicine Finland
(FIMM). The phage genome was assembled using Velvet-assembler (v. 1.2.10) with optimal k-mers per
genome (average coverage ~ × 1600). Genomes of ancestral FCV-1 and evolved FCV-1.01 were aligned
using MUSCLE [44] using default settings suggested by Geneious 7.1.4 (Biomatters Ltd., Auckland,
New Zealand).
4.7. CRISPR Spacer Array Sequencing
In total, 65 bacterial isolates were checked for possible spacer additions in their type II-C CRISPR
locus (CRISPR1) and in type VI-B locus (CRISPR2) using PCR and Sanger sequencing as described
earlier [15]. In brief, CRISPR loci were amplified using the Phusion Flash II polymerase (Thermo Fisher
Scientific, Waltham, MA, USA). The annealing temperature was 65 ◦C for CRISPR1 and 67 ◦C for
CRISPR2, and the elongation step was 30 s for CRISPR1 and 27 s for CRISPR2. Purified PCR products
were sequenced with BigDye® Terminator v3.1. Cycle Sequencing kit using 3130xl Genetic Analyzer
(both from Applied Biosystems, Foster City, CA, USA). Two replicates were done for each read and the
consensus sequences were manually determined using Geneious 9.1.4 (Biomatters Ltd., New Zealand).
4.8. Data Availability
The sequenced phage FCV-1.01 genome was deposited in Genbank under the accession
number MT431535.
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